Showing 8241-8250 of 20875 results for "".
Use of Glucagon and Insulin in a Closed-Loop System
https://reachmd.com/programs/diabetes-discourse/use-of-glucagon-and-insulin-in-a-closed-loop-system/6259/The latest research into the use of glucagon and insulin in a closed-loop system is promising for the management of type 1 diabetes. How will the use of a bihormonal system benefit patients, and what is the path of treatment? Join host Dr. Steven Edelman and his guests, associate professor of biomedUsing Video Games to Improve Children’s Diets
https://reachmd.com/programs/diabetes-discourse/using-video-games-to-improve-childrens-diets/6294/How are video games showing promise as a behavior change strategy to improve children's diets? Newly-funded video-game programs are specifically designed to lower risk of type 2 diabetes and obesity in children. Join host Dr. Steven Edelman and his guest, professor of pediatrics at Baylor College,What is the Relationship Between Insulin Sensitivity and Puberty?
https://reachmd.com/programs/diabetes-discourse/what-is-the-relationship-between-insulin-sensitivity-and-puberty/5755/The emergence of type 2 diabetes in both children and adolescents suggests a relationship between insulin sensitivity and puberty. What are we learning from recent studies and clinical research? Join host Dr. Steven Edelman and his guest, professor of pediatrics at the University of Colorado, Dr. PhEmerging Insulin Pump Technology
https://reachmd.com/programs/diabetes-discourse/emerging-insulin-pump-technology/5108/Will insulin pumps become the preferred therapy for patients with type 2 diabetes who are not at goal? New insulin pump technology and patch pumps are offering a whole new level of customization, an ability to improve glucose control and quality of life. Join host Dr. Steven Edelman and his guest, eGetting to Know GRADE: A Comparative Study of T2D Treatment
https://reachmd.com/programs/diabetes-discourse/getting-to-know-grade-a-comparative-study-of-t2d-treatment/14216/An ancillary study from the landmark GRADE study explores the efficacy of different treatments for type 2 diabetes. What do we need to know about them?Concentrating on the MOMPOD Trial for Metformin Plus Insulin
https://reachmd.com/programs/diabetes-discourse/concentrating-on-the-mompod-trial-for-metformin-plus-insulin/17887/Tune in to find out about how metformin plus insulin can help patients with preexisting diabetes or gestational diabetes."I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
https://reachmd.com/programs/the-convergence/data-barriers-ai-smarter-faster-care/39923/From streamlining research to informing real-time decisions, AI-powered platforms are beginning to reshape how clinicians and researchers access and apply data in patient care. Learn more as Dr. Brian McDonough speaks with Matt Newman, Senior Vice President of Industry Solutions at Manifold, about hPart 1: A Plant-Based Diet for Preventing and Possibly Reversing Coronary Artery Disease
https://reachmd.com/programs/heart-matters/part-1-a-plant-based-diet-for-preventing-and-possibly-reversing-coronary-artery-disease/6249/Beta blockers, anticoagulants, stenting procedures and bypass surgeries: these are all crucial cornerstones of cardiology that have saved and improved the quality of lives for our patients, yet the underlying causes of coronary artery disease aren't addressed by interventions and medications. Can weSpecial Report: What Went Wrong With ACCORD?
https://reachmd.com/programs/clinicians-roundtable/special-report-what-went-wrong-with-accord/3205/What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in moAIP Emerges as a Potential Marker for Diabetic Kidney Risk
https://reachmd.com/programs/clinicians-roundtable/aip-emerges-as-a-potential-marker-for-diabetic-kidney-risk/37220/